Donate Toggle Menu

Leverkusen, January 2010 – Bayer HealthCare and the Kidney Cancer Association (KCA) have announced the European “Advances in Renal Cancer Journalists’ Award” 2010. The prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and takes into account reports which have been published in print media, radio, television or film.

“Renal cancer is one of the most common malignant cancers worldwide with a significant unmet medical need. The objective of this award is to stimulate journalists to contribute publishing knowledge and understanding of renal carcinoma and report on current medical developments”, says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare, Leverkusen, Germany. “Media can play a crucial role in raising awareness of symptoms and risk factors of renal cancer among the public and in calling attention to new, diagnostic therapy options”, adds Carrie Konosky, Director of Development & Public Affairs, Kidney Cancer Association.

Journalists may submit their applications by April 1, 2010, to the Kidney Cancer Association – Project Office, P.O. Box 90 06 48, 51116 Cologne, Germany. The statutes are also available for download online at Bayer HealthCare’s press portal at

The relevant stories must have been published between May 15, 2009, and March 30, 2010. The prize will be awarded for what the jury seems to be the year’s most outstanding medical journalistic publication or program in Europe.

Members of the jury are up to four representatives from journalistic organizations, one urologist and one oncologist, one member of the Kidney Cancer Association as well as one non-voting representative from Bayer HealthCare. The award will be presented in London in May 2010.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover, manufacture and market products that will improve human and animal health worldwide. Find more information at

About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Bayer HealthCare AG
Helmut Schäfers, Tel.: + 49 214-30-58308, Fax: + 49 214-30-50731
e-mail: mailto:[email protected]

The full story can be found in BayNews.